The Function of Renin and the Role of Food-Derived Peptides as Direct Renin Inhibitors by Pihlanto, Anne & Mäkinen, Sari
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 13
The Function of Renin and the Role of Food-Derived
Peptides as Direct Renin Inhibitors
Anne Pihlanto and Sari Mäkinen
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.69513
Abstract
Food proteins contain active peptide fragments encrypted within their structure that can
exert beneficial effects on human health above and beyond their expected nutritional
value. Among many types of food-derived peptides, peptides with antihypertensive
activity have received the most significant attention due to the prevalence of hyperten-
sion and its associated complications with pharmacological interventions. One strategy
for the selection of potential food-derived antihypertensive peptides is to search for
in vitro renin inhibitory activity. Thus far, various food protein-derived peptides and
protein hydrolysates have shown in vitro renin inhibitory capacity. Many of these pep-
tides have induced antihypertensive effects when orally administered to spontaneously
hypertensive rats, and also, antihypertensive effects in hypertensive humans have been
reported. Indeed, the results indicate that antihypertensive food protein-derived pep-
tides may be acting at the same time via multiple pathways at the protein level as well as
at the gene level modulating the renin-angiotensin system. Important knowledge on
structure-function parameters of peptides is increasing constantly, which can greatly
enhance the production and processing of peptides with high physiological efficacy. By
means of novel nutrigenomic approaches, it is possible and, in future, perhaps essential
to investigate the impact of peptides on the expression of genes and hence endeavor to
optimize the nutritional and health effects delivered by peptides. Novel technologies are
available to standardize and stabilize the concentrations of active peptides in the prod-
ucts in down-stream processing. The existing data provide strong potential for develop-
ing new added-value products with scientifically approved health effects for consumers.
This review provides an overview of food-derived peptides that may mediate the antihy-
pertensive activities through inhibiting renin, one of the key enzymes in renin-angiotensin
system, and reviews also the safety and applicability aspects of the these peptides.
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1. Introduction
Cardiovascular diseases (CVD) account approximately one third of the total deaths, totaling ≈17
million annually worldwide [78]. Hypertension is considered one of the key risk factors for
the development of CVD such as coronary heart diseases, peripheral artery disease and stroke,
and kidney disease. Hypertension is often termed as “silent killer” affecting 1 billion people
worldwide and causes up to 9 million deaths every year. In addition to health burden, treat-
ment and prevention of hypertension are also associated with substantial socioeconomic
consequences. A range of synthetic drugs, such as direct vasodilators, diuretics, adrenergic
inhibitors, and angiotensin converting enzyme inhibitors, are commonly used for the treat-
ment of hypertension [50]. The estimated costs for treating hypertension and related diseases
were $156 billion in the USA in 2011 and nearly €110 billion in Europe in 2006. Healthy
lifestyle choices and early treatment for individuals with mild hypertension are of high impor-
tance for reducing the global healthcare costs [50].
In addition to nutritive value of food proteins, they can have various biological activities either
intact or after released during processing or digestion. The active peptide fragments, bioactive
peptides, can exert beneficial effects on human health in addition to nutritional value. These
fragments can be released from various food proteins by gastrointestinal digestion or food
processing. According to the Biopep and BioPD (bioactive peptide database) databases, more
than 1200 different bioactive peptides have been recorded. These peptides have 2–20 amino
acids and molecular masses of less than 6000 Da. Their bioactivity is mainly determined by
their composition and amino acid sequence [17, 56, 64]. Especially, peptides with antihyper-
tensive activity have received the significant attention due to the persistence of hypertension
and its associated complications. Inhibition of angiotensin I converting enzyme (ACE) has
been the main target of these peptides. ACE plays crucial role through renin-angiotensin
system (RAS) in the regulation of blood pressure and electrolyte balance in human body. At
present, the correlation between in vitro and in vivo antihypertensive activities appears to be
weak [18, 23]. To develop effective antihypertensive peptides, it is important to understand the
complex pathophysiology of hypertension and the potential targets where these bioactive
peptides may exert their specific actions. This review provides an overview of food-derived
peptides that may mediate the antihypertensive activities through inhibiting renin, one of the
key enzymes in RAS.
2. Renin-angiotensin-aldosterone system
In cascade system of blood pressure regulation, the renin-angiotensin-aldosterone system
(RAAS) plays a key role. The importance of RAAS in diseases such as hypertension, congestive
heart failure, and chronic renal failure has been recognized; moreover, the inhibition of RAAS
is an effective way to intervene with the pathogenesis of these disorders [11, 43]. Secretion of
renin (EC 3.4.23.15) is the first step in RAAS pathway and, importantly, also the rate-limiting
step of the RAAS by converting angiotensinogen (Ang) into inactive decapeptide angiotensin I
(Ang I), which is converted at the endothelial surface of blood vessels by the enzyme ACE into
angiotensin II (Ang II), the primary effector molecule of the RAAS. Therefore, physiological
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total renin activity, measured as plasma renin activity, can reliably indicate the risk of hyper-
tension, and the inhibition of renin activity by natural products can be explored for the
management of hypertension. Inhibition of renin could provide a more effective treatment for
hypertension as it prevents the formation of Ang-I, which can be converted to angiotensin II
(Ang-II), the vasoconstrictor compound, independent of ACE, by the enzyme chymase. In
addition, unlike ACE which acts on a number of substrates, angiotensinogen is the only
known substrate of renin. ACE inhibitors and AT1 receptor blockers (ARBs) are proven to be
effective therapeutic agents in the treatment of CVD. However, both ACE inhibitors and ARBs
lead to a substantial compensatory rise of circulating active renin and Ang peptides that may
eventually limit their therapeutic potential [24, 67]. Moreover, the increased Ang I can be
converted to Ang II by nonACE pathways, mediated by chymase and chymotrypsin-like
enzyme. In addition to the side effects of ACE inhibitors, such as cough and angioedema, a
meta-analysis of randomized controlled trials in 2010 suggested that ARBs are associated with
a modestly increased risk of new cancer diagnosis, although conclusions about the exact risk of
cancer associated with each particular drug have not been drawn [65]. Therefore, direct renin
inhibition may be an alternative pharmacological approach to RAS inhibition.
The first-generation renin inhibitors were peptide analogs prosegment of renin or substrate
analogs of the amino-terminal sequence of angiotensinogen containing the renin cleavage site
and were synthesized already more than 30 years ago. The second generation inhibitors were
peptidomimetic agents that are dipeptide inhibitors of the active site. However, the clinical use
of these renin inhibitors is limited due to poor metabolic stability and oral bioavailability,
short duration of action, weak antihypertensive activity, and high cost of synthesis [61, 66].
Pepstatin, a statine-containing hexapeptide, is the first reported renin inhibitor, but the inhibitory
activity of pepstatin was remarkably lower against renin than against pepsin [20]. An endoge-
nously expressed renin-binding protein (RnBP) has been reported to inhibit renin activity [68]
based on the selective binding mediated by a leucine zipper (f195–216) in RnBP [33]. The
primary RnBP sequence in the renin-binding region is a valuable information for designing
potent renin-inhibiting peptides that may be identified and released from food proteins using
bioinformatic tools. Aliskiren is the only commercial clinically proven synthetic renin inhibitor
for managing hypertension; it has been approved for use in Europe and the United States from
2007 [34]. It has been found to be a more effective antihypertensive agent than ACE inhibi-
tors [74], but recent clinical evidence suggests that Aliskiren may be harmful to patients with
type 2 diabetes who are at risk of developing cardiovascular and renal diseases [54].
3. Structural characteristics of food protein-derived renin inhibitory
peptides
To reduce the time and cost-intensive steps in the peptide discovery with the conventional
pathway, it is important to understand the relationship between peptide structure and subse-
quent bioactivity. By utilizing the knowledge of structure activity relationship putatively,
active peptide sequences can be released in a targeted manner. To date, the research has
focused in production and characterization of bioactive peptides, and data concerning the
structure-activity relationship are still quite limited.
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Renin is a 335-amino acid, glycosylated aspartic protease belonging to pepsin-like fam-
ily [14, 69]. In contrast to other aspartic proteases such as pepsin, which cleaves a wide variety
of substrates, renin specificity is very restricted. The high specificity of renin catalysis is
explained by the restricted three-dimensional space of the active site. The C- and N-terminal
domains of renin form a deep cleft constructing the active site in which the inhibitors
bind [34, 60]. Angiotensinogen is the highly specific physiological substrate of renin, but new
renin inhibitors—among which the best known is nonpeptidic Aliskiren—have been devel-
oped based on the structural data of the active site [34]. Aliskiren is an orally active renin
inhibitor with a very high binding affinity for renin [77], but it is a complicated molecule and
thus, drugs simpler in structure and with high bioavailability are desirable in the drug market.
The structure of the active site of renin and the binding of Aliskiren is illustrated in Figure 1 [58]. It
is known that the binding to the catalytic aspartate residues is vital for all the protease inhibi-
tors [9]. The active renin inhibitors seem to presuppose interactions with the aspartate residues of
renin (Asp 32 or Asp 215) and the S3sp sub pocket unique for renin. Thus, it has been suggested
that any new renin inhibitor should interact with these sites in the active site of renin [58].
Several renin inhibitor peptide sequences have been identified thus far (Table 1), however,
quite little is known on detailed structure-activity relationship (SAR). Some general character-
istics, such as hydrophobicity and molecular size of the peptide fractions, are suggested to
correlate with the renin inhibitory activity, but the results are somewhat contradic-
tory [2, 31, 36, 40, 44]. Taken together, the position of amino acid residues in the peptide
sequence is more important for the renin inhibition capacity than the actual molecular size or
total net charge.
The presence of N-terminal aliphatic (e.g., leucine, isoleucine, valine) and C-terminal bulky
amino acid residues (e.g., phenylalanine, tryptophan) has been suggested to contribute to
Figure 1. Binding mode of aliskiren as produced from crystallographic data. The protein backbone is shown in ribbons.
Residues of the binding site are displayed as gray sticks and aliskiren as ball and sticks. The right panel shows a zoom in
the active site and the formed H-bonds with aliskiren [58].
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Origin Treatment Identified
sequences
Renin inhibitory
activity in vitro IC50
Antihypertensive effects in vivo, SHRs Reference
Bovine serum albumin Papain, <1 kDa MWCO
fraction of the hydrolysate
SLR 1.18 mg/ml
7.29 mM
ΔSBP32 mmHg after 8 h of oral administration,
200 mg/kg bw
nd
[36]
Bovine blood globulins Papain 1.18 mg/ml nd [39]
Bovine fibrinogen Papain, <1 kDa MWCO
fraction of the hydrolysate
YR
SLR
32% at 1 mg/ml
8.78 mM
7.29 mM
nd
nd
nd
[38]
Bovine and porcine
hemoglobin, collagen and
serum albumin
Papain, pepsin, thermolysin APPH, IIY, PPL,
PPG, PFG, IPP,
LPP
15–28% at 1 mg/ml nd [37]
Chicken skin protein Alcalase, pepsin + pancreatin 1.6–2.2 mg/ml ΔSBP 31.33 mmHg after 6 h of oral
administration, 100 mg/kg bw
[52]
Cod muscle proteins pepsin + trypsin +
chymotrypsin
RP-HPLC fraction of the
hydrolysate
43% at 1 mg/ml
63% at 1 mg/ml
ΔSBP 19 mmHg after 2 h of oral administration,
200 mg/kg bw
ΔSBP 40 mmHg after 2 h of oral administration,
30 mg/kg bw
[26]
Kidney bean protein Alcalase, <1 kDa and 5–10
kDa MWCO fractions of the
hydrolysate
40% at 1 mg/ml nd [48]
Flaxseed protein Pepsin, ficin, trypsin, papain,
thermolysin, pancreatin, and
Alcalase
Trypsin-pronase
Cationic, R-rich
peptides
1.22–2.81 mg/ml
44.5% at 7.5 mg/ml
nd
ΔSBP 17.9 mmHg after 2 h of oral administration
200 mg/kg bw
[71, 73]
Red seaweed (Palmaria
palmata) protein
Papain IRLIIVLMPILMA 42% at 1 mg/ml
3.344 mM
ΔSBP 34 mmHg after 24 h of oral administration,
50 mg/kg bw
ΔSBP 33 mmHg after 24 h of oral administration,
3 mg/kg bw
[21, 22]
Hemp seed protein Pepsin + pancreatin WYT, SVYT,
IPAGV
0.81 mg/ml
0.054 mM (WYT), 0.063
mM (SVYT), 0.093 mM
(IPAGV)
ΔSBP 30 mmHg after 8 h of oral administration,
200 mg/kg bw
ΔSBP 13.36 mmHg after 4 h of oral
administration, 30 mg/kg bw
[29, 30]
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Origin Treatment Identified
sequences
Renin inhibitory
activity in vitro IC50
Antihypertensive effects in vivo, SHRs Reference
Hemp seed protein Alcalase, pepsin, papain,
pepsin + pancreatin
0.08–0.24 mg/ml ΔSBP 25.33 mmHg after 4 h of oral
administration, 200 mg/kg bw
[44]
Pea protein Thermolysin, <3kDa MWCO
fraction of the hydrolysate
17% at 1 mg/ml ΔSBP 19 mmHg after 4 h of oral administration,
200 mg/kg bw
ΔSBP 29 mmHg after 8 weeks of oral
administration to Han:SPRD-cy, 0.1% of diet. Renal
expression of renin mRNA levels was reduced
significantly.
ΔSBP 6 mmHg in a 3-week human intervention
trial
[41]
African yam bean seed Alcalase
RP-HPLC fraction of the
hydrolysate
35% at 1 mg/ml
55% at 1mg/ml
[1]
Rapeseed and canola
protein
Alcalase, pepsin, trypsin,
pancreatin
Alcalase
Pepsin + pancreatin
RALP, LY, TF
GHS
15.80% at 1 mg/ml
0.968 mM (RALP), 1.868
mM (LY), 3.061 mM (TF)
0.320 mM
ΔSBP 25 mmHg (pepsin) and 34 mmHg
(Alcalase) after 4 h of oral administration, 200 mg/
kg bw
ΔSBP 12 mmHg (TF), 26 mmHg (LY) and 16
mmHg (RALP) after 6 h of oral administration, 30
mg/kg bw
ΔSBP 17 mmHg after 6 h of oral administration,
30 mg/kg bw
[2, 30, 31]
Table 1. Food protein-derived renin inhibitory peptides and antihypertensive effects in vivo.
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higher renin inhibitory activity of dipeptides [71]. For example, dipeptides Leu-Tyr, Ile-Trp,
and Thr-Phe have been reported to inhibit renin activity with IC50 values of 1.8, 2.3, and 3.7 mM,
respectively [30]. The structures of these peptides mostly agree with the characteristics pro-
posed to contribute to renin inhibition. The importance of C-terminal bulky hydrophobic
amino acid residue was also observed by changing the position of amino acids residues from
Thr-Phe to Phe-Thr, which resulted to substantial decrease in renin inhibition [30, 71]. How-
ever, highly hydrophilic peptides, such as Gly-His-Ser, have also been reported to inhibit renin
with IC50 value of 1.09 mM [31]. Also, a cationic tetrapeptide Arg-Ala-Leu-Pro and a 13-amino
acid residue, Ile-Arg-Leu-Ile-Ile-Val-Leu-Met-Pro-Ile-Leu-Met-Ala, have also shown rather
high renin inhibitory potency [22, 30]. The highest renin inhibitory activity among the reported
food protein-derived peptides thus far is 0.054 mM for Trp-Tyr-Thr produced from hemp seed
protein [27]). Taken together, more research is needed to gain more knowledge on detailed
SAR for designing potential renin inhibitory peptide sequences as physiological antihyperten-
sive agents.
Quantitative computational tools are increasingly applied in medicinal and pharmaceutical
drug discovery. At present, the relationship of peptide structure and bioactivity, especially
the enzyme inhibitors of ACE are known in some extent. The knowledge of the active
peptide sequences enables utilization of quantitative structure-activity relationship model-
ing (QSAR) for evaluating the crucial physicochemical features of the peptide for the effec-
tive bioactivity. A small number of QSAR studies have been carried out on ACE-inhibitory
peptides [59, 66] however, no studies have been carried out with seeking potential renin
inhibitory peptides.
4. Bioavailability
To induce health effects in vivo, peptides need to reach the physiological target organs in intact
and active conformation. Considering the renin inhibition, there are three main barriers and
hydrolytic threats on the way to the in vivo outcome: the digestive proteinases in the gastroin-
testinal tract, enzymes in the site of absorption, and serum peptidases in the circulation. Thus
far, the published data concerning the bioavailability of the peptides, which have shown
in vitro renin inhibitory activity, are very limited. This makes it very difficult to predict the
in vivo antihypertensive effect of the in vitro renin inhibitory peptides. However, some struc-
tural characteristics have been shown to correlate with the bioavailability of, e.g., ACE-
inhibitory peptides. These general peptidic characteristics can be considered with renin inhib-
itory peptides as well.
At first, after oral ingestion bioactive peptides need to resist the hydrolytic actions in stomach
by pepsin and pancreatic peptidases, including trypsin, elastase, and chymotrypsin, and
further, carboxypeptidases in the small intestine. Several different methods have been applied
to model the gastrointestinal digestion in vitro. Most of the methods not only concern utiliza-
tion of commercial porcine enzyme mixtures (e.g., Refs. [42, 46, 75]) but also human digestive
liquids have been utilized [19, 49]. Due to the variation in the methods, the comparison of the
results across the studies is difficult and thus, a harmonization of the various in vitro methods
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would be important. A consensus for a static process to model the digestion of plant secondary
metabolites has been constructed based on in vivo data [3]. Indeed, the future research should
focus more on the in vivo bioavailability of the peptides and based on the correlation with
in vivo data, a harmonized in vitro method could be proposed.
The peptides are exposed to peptidolytic digestion also on the brush border membrane of the
intestine. There are number of peptidases with varying specificities bound on the intestinal
epithelial cells. It has been suggested that dipeptide and tripeptide tend to resist the gastric and
duodenal digestion and also the hydrolytic action of peptidases at the brush border mem-
brane. These small peptides can be absorbed by active transcellular transport or by passive
process [63]. To study the absorption in vitro, the monolayer of intestinal cell lines, such as
Caco-2 cells, simulating intestinal epithelium, is commonly utilized. Clinical data concerning
the bioavailability of bioactive peptides are very restricted; however, ACE-inhibitory lactotri-
peptides, Ile-Pro-Pro and Val-Pro-Pro, have been detected in human and animal circulatory
system after oral ingestion [25].
5. Effects of food protein-derived renin inhibitory peptides in vitro and
in vivo
The most widely utilized method for assessing the renin inhibitory potential in vitro is a
fluorometric assay utilizing a human recombinant renin (Cayman Chemical, MI, USA). Recent
data indicate that some food protein-derived hydrolysates and peptides possess in vitro renin
inhibitory activity. Inhibiting activity against human recombinant renin has been reported, for
instance, for hemp seed, pea, bovine blood, and chicken skin protein-derived hydrolysates
produced by various food grade proteases (Table 1).
Among the protein hydrolysates, the highest renin inhibitory activities have been reported for
hemp seed protein hydrolysates with IC50 values of 0.08–0.81 mg/ml [27, 44]. These activities
are at the same level with the synthetic renin inhibitor Z-Arg-Arg-Pro-Phe-His-Sta-Ile-His-Lys-
(Boc)-OMe [22]. Alcalase has yielded to very active renin-inhibiting hydrolysates (e.g., Refs.
[2, 30]), and also pancreatin and papain have produced high renin inhibitory activity (e.g.,
Refs. [21, 27]). Papain has also exhibited good prospects in silico in releasing renin inhibitory
peptides from, for instance, bovine fibrinogen [37]. Moreover, simulated food protein hydro-
lysis with gastrointestinal enzymes has also resulted in products with renin inhibitory activi-
ties [27, 51]. Taken together, the efficiency of the protease to release renin inhibitory peptides
seems to depend on the parent protein matrix. Thus, in silico tools are recommended to be
utilized prior to the in vitro experiments to predict the efficacy of proteases with the particular
protein matrixes.
Spontaneously hypertensive rats (SHR) are widely used animal model to assess the antihyper-
tensive effects by in vivo experiments. This animal model is applied in short- and long-term
manners, for example, to study the antihypertensive effects of milk protein-derived pep-
tides [18, 23]. Recently, food protein-derived renin-inhibiting peptides and protein hydroly-
sates have induced antihypertensive effects when orally administered to spontaneously
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hypertensive rats. Decreases in SBP by 19–33 mmHg have been reported for instance, for
enzymatic hydrolysates of chicken skin, red seaweed (Palmaria palmata), hemp seed, and pea
protein (Table 1). Generally, the purified renin inhibitory peptides and RP-HPLC fractions
have exerted the antihypertensive activities at lower dosage (30 mg/kg bw) compared to the
crude protein hydrolysates and membrane-filtrated fractions, which has shown similar anti-
hypertensive effects with 100–200 mg/kg bw (Table 1). Hydrolysates and peptides have shown
dual inhibition against renin and ACE, or modulation capacity on the RAAS gene expression.
Thus, the antihypertensive effects are not solely due to the renin inhibition (e.g., Ref. [41]). For
example, egg-derived pentapeptide RVPSL has been recently shown to decrease renin mRNA
expression in the kidney of SHRs with a dosage of 50 mg/kg bw administered daily for 4
weeks [79]. Also, weakly active renin-inhibiting peptides have been shown to display physio-
logical antihypertensive activity. Aweakly active pea protein hydrolysate (19% renin inhibition
at 1 mg/ml) exhibited SBP lowering effects in SHRs and in a kidney disease rat model and was
found to downregulate renal expression of renin mRNA in the rat model (Table 1). Also, the
pea protein hydrolysate showed antihypertensive effects in hypertensive humans in a 3-week
intervention trial (Table 1). This indicates that antihypertensive food protein-derived peptides
may be acting at the same time via multiple pathways at the protein level as well as at the gene
level modulating the RAAS.
6. Production of food protein-derived renin inhibitory peptides
A general challenge is how to process the protein hydrolysates further into peptide products
with high yield and biological efficacy. Careful choice of suitable enzymes and conditions such
as temperature, hydrolysis time, degree of hydrolysis, and enzyme-substrate ratio are crucial
for production of peptides with targeted bioactivities and functional properties. Hydrolysis
process is recommended to be performed as a continuous process rather than traditional batch
process to reduce the enzyme consumption and increase the efficacy [45, 76]. One advantage of
enzymatic hydrolysis process is the feasibility in pilot and industrial scale production [6, 7, 28].
To enhance the bioactivity, the active peptides should be concentrated after protein hydrolysis.
Size, net charge, and hydrophobicity of the peptides have an important role to select the most
suitable techniques to enrich the active peptides. The commonly used techniques include
ultrafiltration membranes and chromatographic techniques to obtain an uniform product with
the desired range of molecular mass (e.g. [15]). For example, ultrafiltration with 1 kDa mem-
brane has been utilized to concentrate renin inhibitory peptides from rapeseed protein
hydrolysate into permeate [36, 38, 48]. In addition to separation based on molecular size,
ultrafiltration can be applied to separate peptides according to the net charge. This
electrodialysis-ultrafiltration can be utilized to separate anionic, cationic, and neutral peptides
of corresponding size range [5, 16, 17]. Large-scale chromatographic methods, used in sugar
recovery and wastewater treatments, have been used to enrich peptides from hydrolysates and
to separate off ineffective peptides or further undesirable components of the hydrolysates,
such as colors, abnormal flavors, and/or salts [10]. Large-scale food-grade processing protocols
for designed peptides fractions are needed for further development. Understanding the
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structural characteristics of peptides with targeted bioactivity and exploitation of these char-
acteristics is a crucial requirement for this approach.
7. Safety aspects of peptides
The term food allergy refers to an immune response directed toward food and affects approx-
imately 8% of children and 1–2% of adults, and its frequency is increasing [35]. Most allergens
reacting with IgE antibodies are proteins found in peanuts, soybeans, tree nuts, milk, egg, fish,
crustaceans, and wheat [53, 70].
European Food Safety Authority (EFSA) encourages the use of in silico tools for initial predic-
tion of potential allergens from food proteins [8]. Although the toxicity and the allergenicity of
food products must be assessed also in vitro and in vivo, the in silico tools can be also used to
predict the toxicity of peptides [29]. The available bioinformatics-based allergen prediction
tools consist of two groups. The first group is based on searches for sequence similarities
following the Codex alimentarius guidelines produced by the Food and Agriculture Organi-
zation (FAO) and the World Health Organization (WHO), which states that a “protein is
potentially allergenic if it either has an identity of over six contiguous amino acids or a
minimum of 35% sequence similarity when compared to known allergens” [13]. The second
group utilizes databases aiming to identify conserved, allergenicity-related linear motifs [13].
AlgPred (http://www.imtech.res.in/raghava/algpred/) integrates different approaches by means
to predict the allergenicity of proteins [62].
After ingestion of food, proteins are naturally hydrolyzed in the gastrointestinal digestion. The
digestion often produces peptides with low MW and free amino acids, which are transported
across the intestine wall [57]. Highly hydrolyzed proteins and peptides with low MW are not
generally toxic and are known to be less allergenic than the native proteins and are widely used
in the formulation of hypoallergenic infant foods [32]. However, toxic peptides have been identi-
fied from plant as well as animal origin, and they can result in acute, physiological effects, and
death. Toxic peptides are usually rich in residues like Asn, Cysm His, and Pro, whereas nontoxic
peptides contain dominantly residues Ala, Arg, Gln, Ile, Leu, Lys, Met, Phe, Thr, and Val. [53].
Altogether, the in silico assessment of toxicity is not enough, and in vivo studies in animal
models should be carried out before human consumption. The in vivo assessment of the
toxicity of food products must be carried out following the guidelines proposed by interna-
tional authorities. Large quantities of scientific evidence and tests need to be carried out on
vertebrate models and cell lines, or unicellular microbial species [47]. Multiple peptide toxicity
studies have been carried out in animal models to date [12, 57].
8. Application
Intensive research on bioactive peptides being carried out around the world has already led to
the introduction of a wide range of commercial products. The bioactive peptides offer an
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exciting opportunity in the area of the development of novel functional foods which in turn
could contribute to the prevention and management of certain diseases, such as hypertension,
type 2 diabetes, or obesity, and more broadly metabolic syndrome. The functional foods or
food ingredients containing milk-derived bioactive peptides, such as the fermented milk
Calpis, are already in the market [55]. The claims related to peptides are hypotensive proper-
ties, aiding mineral absorption, improving athletic performance, and reducing stress. Since
1991, the Ministry of Health and Welfare in Japan has awarded the status of Food of Specific
Health Use (FOSHU) to foods with scientifically validated health claims. Since then, anti-
hypertensive peptides, such as Val-Pro-Pro, Ile-Pro-Pro, Val-Tyr, have obtained FOSHU
approval [55]. In Europe, applications for nutrition and health claims are submitted to the
European Food Safety Authority (EFSA) under Regulation 1924/2006 and are evaluated by
Dietetic Products, Nutrition and Allergies (NDA) panel of scientific experts [4]. There are three
categories of health claims as defined by EU legislation. Article 13.1 claims are defined as new
function or emerging science claims. Recently, the aspects concerning the scientific information
needed for the use of a health claim in the functional food product labeling and marketing
should include the scientific evidence on the beneficial effects of the product. The characteri-
zation of food components with in vitro and animal models is needed but they are not
sufficient to substantiate the biological functionality in humans. Human studies to investigate
the effects of food or food components on reliable markers, such as blood pressure and
oxidative damage, are essential. There is still a lot of confusion within the food industry as to
what evidence is required with the EU. Regarding the applications already processed, the
Commission of European Communities has not yet authorized any claims relating to the effect
of bioactive peptides in foods.
9. Conclusions
There is no doubt that the hydrolysis of proteins gives rise to diversity of peptides, some of
them displaying remarkable functionalities relevant to human health. The research should
encourage the industry to invest more in the added-value products with scientific evidence of
health benefits. To this end, novel technologies are available to standardize and stabilize the
concentrations of active peptides in the products by means of chromatographic, membrane
separation techniques, and encapsulation. Important structure-function parameters of pep-
tides are increasing constantly, which can greatly enhance the production and processing of
peptides. With improved understanding of the structure-activity relationship, we may be able
to design targeted enzyme hydrolysis strategies to release these peptides.
According to Foltz et al. [25], it appears that it is only valid to propose efficacy once the peptide
exhibits reasonable proteolytic stability and physiologically relevant absorption, distribution,
metabolism, and excretion profiles. In this field, more in-depth topics include the stability of
the biological activity of peptides, during processing as well as in vivo in the body before being
absorbed and transported to the target site. Greater understanding of the biological fate of
peptides and the site of action will allow delivery or an effective dose and formulation of the
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peptides to ensure that they reach their target sites. Moreover, we need to gain better under-
standing of the relationship between these in vitro activities and, especially, long-term health
benefits in humans and establish appropriate biomarkers of biological efficacy. For example,
the extent of the antihypertensive effects has been suggested to depend on the nature of
delivery system, dose, study duration, genetic background of the subjects, and stages of
hypertension (reviewed in [72]). Furthermore, molecular studies are needed to assess the
mechanisms by which bioactive peptides exert their activities in the body. To this end, it may
be necessary to employ proteomic and metabolomic methods. By means of these novel
nutrigenomic approaches, it is possible and, in future, perhaps essential to investigate the
impact of peptides on the expression of genes and hence, endeavor to optimize the nutritional
and health effects delivered by peptides.
The safety of all novel peptides intended for food or pharmaceutical uses should be tested in
accordance with international and national food safety regulations. In cases of products
intended to be marketed in the EU member states, the novel food legislation has to be
observed. Other challenges with dietary bioactive peptides are posed by health claims, which
in the EU countries are strictly regulated and require science-based documentation before
approval by the European Commission. At present, there are worldwide efforts to harmonize
these regulations so as to develop fair global food marketing and protect consumers against
false or misleading product information.
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